Ultimately, while DPP-4 inhibitors offer a promising avenue to augment GLP-1 levels and support metabolic control in patients with heart failure, the potential overexpression of DPP-4 and its extensive influence on GLP-1 and other bioactive peptides suggest that the net effects on cardiac health are multifactorial. This evidence concerns the gene GCG and heart failure.